Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World palbociclib study in brazil: what happened with 121 patients?

NCT ID NCT05505175

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 121 women in Brazil with a certain type of advanced breast cancer (HR+/HER2-). Researchers tracked how doctors prescribed palbociclib combined with other drugs in everyday practice, not in a strict trial setting. The goal was to describe patient backgrounds, treatment patterns, and outcomes like how long the cancer stayed under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
palbociclib (a targeted cancer drug) combined with letrozole or fulvestrant
What this could lead to
If successful, this study could help doctors understand how well palbociclib combinations work in everyday Brazilian clinics, potentially improving treatment guidelines for advanced breast cancer.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other countries or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST CARCINOMA

Contacts and locations

Locations

  • Centro Especializado de Oncologia de Florianópolis

    Florianópolis, 88032-005, Brazil

  • Centro de Tratamento de Tumores Botafogo

    Rio de Janeiro, 22.250-905, Brazil

  • Ensino E Terapia de Inovação Clínica Amo - Ética

    Salvador, Estado de Bahia, 41.830-492, Brazil

  • Hcor - Associação Beneficente Síria

    São Paulo, 04004-030, Brazil

  • Hospital Araújo Jorge

    Goiânia, Goiás, 74605-070, Brazil

  • Hospital Paulistano - INSTITUTO DE EDUCAÇÃO, PESQUISA E GESTÃO EM SAÚDE

    São Paulo, 01323-000, Brazil

  • Hospital Sírio Libanês

    Brasília, Federal District, 70200-730, Brazil

  • Instituto D'or de Pesquisa e Ensino

    Recife, 50070-480, Brazil

  • Instituto D´Or de Pesquisa E Ensino - Brasília

    Brasília, Federal District, 70.390-700, Brazil

  • Instituto D´or de Pesquisa e Ensino

    Rio de Janeiro, 22281-100, Brazil

  • Instituto de Educação, Pesquisa e Gestão em Saúde

    Rio de Janeiro, 22793-080, Brazil

  • Instituto de Mastologia e Oncologia

    Goiânia, 74110-060, Brazil

  • NOB - Nucleo de Oncologia da Bahia

    Salvador, Estado de Bahia, 40170-110, Brazil

  • Oncoclínicas Do Brasil Servicos Médicos S/A - Oncocentro

    Belo Horizonte, Minas Gerais, 30.360-680, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.